Low-Dose International Normalized Ratio Self-Management: A Promising Tool to Achieve Low Complication Rates After Mechanical Heart Valve Replacement
|
|
- Richard Cannon
- 6 years ago
- Views:
Transcription
1 Low-Dose International Normalized Ratio Self-Management: A Promising Tool to Achieve Low Complication Rates After Mechanical Heart Valve Replacement Heinrich Koertke, MD, Armin Zittermann, PhD, Kazutomo Minami, MD, Gero Tenderich, MD, Otto Wagner, Mahmoud El-Arousy, MD, Arno Krian, MD, Juergen Ennker, MD, Uwe Taborski, MD, Wolf Peter Klövekorn, MD, Rainer Moosdorf, MD, Werner Saggau, MD, Michiel Morshuis, MD, Jan Koerfer, MD, Dirk Seifert, MD, and Reiner Koerfer, MD Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North-Rhine-Westphalia Bad Oeynhausen, Clinic of the Ruhr University Bochum, Bochum; Evangelisches Johanniter Klinikum, Duisburg; Heart Center Lahr, Lahr; Kerckhoff- Klinik, Bad Nauheim; Heart Center Marburg, Clinic of the Philipps-University Marburg, Marburg; and Klinikum Ludwigshafen, Clinic for Heart Surgery, Ludwigshafen, Germany Background. International normalized ratio (INR) selfmanagement can significantly reduce INR fluctuations, bleeding, and thromboembolic events compared with INR control managed by general practitioners. However, even patients with INR self-management may have an increased risk of bleeding if their INR value is above 3.5. This study evaluated the compliance, clinical complications, and survival of patients after mechanical heart valve replacement with low-dose INR self-management compared with conventional-dose anticoagulation. Methods. Group 1 (n 908) received low-dose anticoagulation with a target INR range of 1.8 to 2.8 for aortic valve replacement and 2.5 to 3.5 for mitral or double valve replacement. Group 2 (n 910) received conventional-dose anticoagulation with a target INR range of 2.5 to 4.5 for all heart valve prostheses. Results. In groups 1 and 2, 76% and 75% of INR values, respectively, were in the target range. Results did not differ according to schooling and age. The rate of thromboembolic events per patient year was 0.18% in group 1 and 0.40% in group 2 (p 0.210). The rate of bleeding complications was 0.74% for group 1 and 1.20% for group 2(p 0.502). In most patients with clinically relevant bleeding, these complications occurred although their measured INR values were below 3.5. The survival rate did not differ between the study groups (p 0.495). Conclusions. Low-dose INR self-management is a promising tool to achieve low hemorrhagic complications without increasing the risk of thromboembolic complications. INR self-management is applicable for all patients in whom permanent anticoagulation therapy is indicated. Even INR values below 3.5 can bear the risk of bleeding complications. (Ann Thorac Surg 2005;79: ) 2005 by The Society of Thoracic Surgeons During recent decades, heart valve replacement has become a frequent intervention in cardiovascular medicine. Mechanical heart valves account for approximately 70% and biological heart valves for approximately 30% of totally implanted heart valves. Because biological heart valves are durable for only 8 to 12 years in the aortic position and only 6 to 8 years in the mitral position, these implants are restricted to elderly patients [1]. Compared with biological heart valves, mechanical heart valves bear a much higher risk of thromboembolism; thus, anticoagulation therapy after mechanical heart valve replacement is mandatory. Hemorrhage is a possible complication of anticoagulation therapy. Bleeding and thromboembolism account for 75% Accepted for publication Sept 7, Presented at the Forty-first Annual Meeting of The Society of Thoracic Surgeons, Tampa, FL, Jan 24 26, Address reprint requests to Dr Koertke, Herz- und Diabeteszentrum NRW, Georgstrasse11, Bad Oeynhausen, Germany; hkoertke@ hdz-nrw.de. of all complications after mechanical heart valve replacement. The risk of complications in conjunction with ongoing anticoagulation therapy is considerably higher when international normalization ratio (INR) values fluctuate strongly. When anticoagulation-induced complications occur, as many as 60% of the coagulation values controlled are outside the therapeutic range [2, 3]. INR self-management allows a close-meshed control of the intensity of anticoagulation. The Early Self-Controlled Anticoagulation Trial I (ESCAT I) showed that selfmanagement could reduce the INR fluctuations. Approximately 78% of the INR values of patients under INR self-management were within the therapeutic range compared with only 60% of the INR values in those patients managed by their family doctors [4]. Moreover, ESCAT I demonstrated a significant reduction in complications and in the mortality rate of patients with INR self-management compared with conventionally treated patients [5]. Until recently, a therapeutic INR range from 2.5 to 4.5 has been regarded as necessary to prevent thromboembolism; however, this range includes a zone of higher risk for bleeding 2005 by The Society of Thoracic Surgeons /05/$30.00 Published by Elsevier Inc doi: /j.athoracsur
2 1910 KOERTKE ET AL Ann Thorac Surg LOW-DOSE INR SELF-MANAGEMENT 2005;79: complications, beginning with an INR that exceeds 3.5. In addition, there is evidence from recent data analyses on oral anticoagulation and risk of death that an INR target value of 3.5 may already be too high [6]. In that earlier study, a minimum risk of death was attained at 2.3 INR for patients with mechanical heart valve prostheses. With an increase of 1 U of INR above 2.5, the risks of death from cerebral bleeding and from any cause were nearly doubled. Recently, target ranges of 2.0 to 3.0 INR for aortic valve prostheses and 2.5 to 3.5 INR for mitral valve prostheses have been recommended [7]. Nevertheless, these guidelines are based on only a few studies, and controlled prospective trials on complication rates in patients who are on low-dose INR self-management are almost completely lacking. Encouraged by the high percentage of INR values lying within the therapeutic range in the ESCAT I study, we began ESCAT II to eliminate the high-risk zone for bleeding. ESCAT II was thus designed to assess the effects of a low-dose INR therapeutic range accompanied by self-management. ESCAT II is an ongoing prospective, controlled, randomized multicenter study with 3300 patients. The study began in October We recently presented the first results of a planned interim analysis indicating that INR selfmanagement permits lower anticoagulation levels after mechanical heart valve replacement [8]. In a very recent meta-analysis, however, it was assumed that patients with mechanical heart valves would benefit from a treatment strategy with a target INR higher than 3.0 [9]. We therefore performed an extended analysis of our interim data to further evaluate our strategy of low-dose INR self-management. Material and Methods Patients The interim analysis comprised 1818 patients, 18 to 82 years of age. All participants underwent a mechanical aortic, mitral, or double valve replacement. Exclusion criteria were a contraindication to phenprocoumon (eg, allergy), known ulcerous disease with bleeding tendency, hypocoagulability or hypercoagulability (medical history), and an age less than 18 years. All patients gave written informed consent to the study procedures. The study protocol was approved by the ethics committee of each of the six participating centers. Study Protocol Implanted were 840 Medtronic Hall heart valves (Medtronic GmbH, Düsseldorf, Germany), 895 St. Jude Medical heart valves (St. Jude Medical GmbH, Nürnberg, Germany), and 83 other heart valves from different manufacturers (38 Carbo- Medics valves [Austin, TX]; 29 ATS Medical valves [Minneapolis, MN], 2 Mosaic valves [Medtronic, Minneapolis, MN], 2 Omnicarbon valves [MedicalCV, Inner Grove Heights, MN], 8 On-x valves [MCRI, Austin, TX], and 4 Pyrolite valves [Sulzer- Medica, Austin, TX]). After heart valve replacement, the patients were randomly assigned to either the low INR range (group 1) or the conventional INR range (group 2) group. The conventional group (n 908) had a target INR range of 2.5 to 4.5. The low-dose group (n 910) had a target range of 1.8 to 2.8 for aortic valve recipients and 2.5 to 3.5 for mitral or double valve recipients. The study began in October For this interim analysis, only data that were available until December 2001 were included. All study participants joined a training course for INR self-management at our clinics which is based on the assumption that patients who depend on long-term anticoagulation therapy are able to selfresponsibly determine the INR values and correct the dose of anticoagulants. Initial training began between postoperative day 6 and day 11. Training lasted 5 hours and was terminated by a short test. INR measurements were performed with a coagulation monitor (CoaguCheck S, Roche Diagnostics, Mannheim, Germany). During the training course, the patients were instructed that any INR value between the two extremes was acceptable. However, the patients of the low-dose group were also instructed that the desired INR value should be close to 2.3 (aortic valve recipients) or 3.0 (mitral or double valve recipients), whereas the patients of the conventional dose group were instructed that the desired INR value should be close to 3.0. INR values were usually determined weekly. The patients had to check their INR values once a week during the first study year and once a fortnight during the second study year. Results had to be transmitted to the study center every month. All patients had to visit their study center for a cardiologic check-up every 6 months. During that visit, the patients had to demonstrate that they were able to measure the INR values correctly and interpret the results accordingly. The third phase of the training consisted of telephone care and control and the possibility of a consultation around the clock. The patients had the opportunity to adjust their anticoagulation therapy with the help of specialized cardiologists. Patients were asked to report any complication to the study center immediately. Thromboembolism complications and bleeding events were graded as I, II, or III. Briefly, a grade III thromboembolism was defined as heart valve prosthesis thrombosis or severe thromboembolism that required inpatient treatment or caused long-term impairment, including transient ischemic attacks. A grade II thromboembolism required outpatient treatment but caused no permanent impairment, and a grade I thromboembolism (questionable events) required no medical treatment. Grade III bleeding was defined as severe bleeding that required transfusion, surgical or endoscopic intervention, inpatient care, or that caused long-term impairment. Grade II bleeding led to outpatient medical care but did not require surgical or endoscopic intervention, and grade I bleeding (mild bleeding) required no medical treatment. Only grade III complications were used for data analysis, as previously described [8]. Data collection was both passive and active: Patients were asked to inform their local study centers when a thromboembolism or bleeding complication had occurred. Moreover, they were asked during their follow-up visits whether a complication had occurred within the last 6 months. All reports of grade III complications were sent from the emergency hospital to the study center and were double-checked by a center cardiologist. Finally, the study center in Bad Oeynhausen contacted each local study
3 Ann Thorac Surg KOERTKE ET AL 2005;79: LOW-DOSE INR SELF-MANAGEMENT 1911 Table 1. Characteristics of Patients With Low-Dose International Normalized Ratio (INR) Self-Management and With Conventional Dose INR Self-Management Low Dose n 910 Conventional Dose n 908 Significance (p) Age (yrs) NS Male (%) Body weight (kg) Body height (meter) Smoker (n) NS Hypertension (n) NS Hypercholesterolemia (n) NS Atrial fibrillation (n) NS Red blood cells (10E12/I) NS Hemoglobin (g/dl) NS Hematocrit (%) NS Fibrinogen (mg/dl) NS Total cholesterol (mg/dl) NS HDL-cholesterol (mg/dl) NS LDL-cholesterol (mg/dl) NS Blood pressure, systolic (mm Hg) NS Blood pressure, diastolic (mm Hg) NS Heart rate (beats/min) NS LDL low-density lipoprotein; HDL high-density lipoprotein; NS not significant. center regularly to get information about the number of bleeding and thromboembolism events. Two years after valve implantation, the patients stopped sending their INR values to the study center. Only grade III complication and deaths that occurred within 24 months of heart valve replacement were used for data analysis. Statistical Analysis All statistical evaluations were performed with the Statistical Package for Social Sciences (SPSS), version 11 (SPSS, Chicago, IL). For comparative evaluations, the 2 test and the Student t test (normal distributed data) were used. Normal distribution of the data was tested by the Kolmogorov-Smirnov test. Freedom from grade III complications and survival rates were calculated with the Kaplan-Meier product-limit estimator. Differences in grade III complications and survival rates between the low-dose INR group and the conventional-dose INR group were tested with the log-rank test. Data analysis was based on the assumption that for a statistical power of 0.8 ( 0.05; 0.20), a reduction of grade III complications by 2% (eg, from 3% to 1%) or an increase by 3% (eg, from 3% to 6%) would require a study population of 1690 patients or 1310 patients. A study population of 3300 or 2360 patients would be necessary to achieve an value of 0.01 under otherwise similar assumptions. A p value less than 0.05 (two-tailed test) was considered statistically significant; p values of Kaplan-Meier survival analysis greater than 0.05 and less than 0.15 were considered borderline significant [10]. Data were expressed as mean values standard deviation unless otherwise stated. Results In the low-dose INR group, 81% of patients received aortic valve prostheses and 12.5% and 6.5% received double valve prostheses in mitral and double positions, respectively. The corresponding values for the conventional INR group were 77%, 16.5%, and 6.5%, respectively. Baseline characteristics of the study groups are given in Table 1. The conventional-dose INR group included a slightly higher percentage of women, had patients with a lower body weight, and the body height tended to be lower compared with the low-dose INR group. Cardiovascular risk factors such as smoking, hypertension, and atrial fibrillation were equally distributed in both study groups, and the study groups had similar laboratory data. The average weekly phenprocoumon dose was 17.4 mg in the conventional-dose group and 16.5 mg in the low-dose group. The average observation time was 13 months/ patient (range, 2 to 24 months), leading to a total observation time of 2848 patient years. Of the 1818 patients, 239 (13.15%) terminated the study prematurely for a variety of reasons: they could not manage the device (n 54); they had more confidence in their physicians (n 65); measurements were stopped by illness (n 32); patients were noncompliant (n 44) or not interested in INR selfmanagement (n 9); they missed or had incomplete instructions for INR self-management (n 21); health insurance did not pay for the device (n 2), and travel costs to the place of reexamination were too high (n 3). Nine patients terminated with no comment. The percentage of study dropouts in the low-dose and the conventional-dose groups did not differ significantly (data not shown). The patients submitted 73,148 INR values to the study centers during the investigation period. Mean INR values in patients with aortic valve replacement were 2.41 in the low-dose group and 2.80 in the conventional-dose group, whereas in patients with mitral and double valve replace-
4 1912 KOERTKE ET AL Ann Thorac Surg LOW-DOSE INR SELF-MANAGEMENT 2005;79: Fig 2. International normalized ratio (INR) values within the therapeutic range in patients with low-dose (solid squares) or conventional-dose (solid circles) INR self-management over time (reha rehabilitation.) Fig 1. International normalized ratio (INR) values of patients with INR self-management: (A) Low dose of anticoagulation and aortic valve replacement. (B) Conventional dose of anticoagulation and aortic valve replacement. (C) Low dose of anticoagulation and mitral or double valve replacement. (D) Conventional dose of anticoagulation and mitral or double valve replacement. ment, they were 2.90 in the low-dose group and 3.10 in the conventional-dose group (Fig 1). Approximately 76% of the INR values measured in the low-dose group and approximately 75% of the INR values in the conventional-dose group were within group s target range. These values remained very stable in both outpatient groups throughout the study period (Fig 2). Of the INR values submitted, 3.86% were below the lowest target range (1.8 INR) and 1.08% were above the highest target range (4.5 INR). As expected, more INR values in the low-dose group were below 1.8 INR compared with the conventional-dose group (5.12% vs 2.57%). Unsurprisingly too, only 4.76% of the values in the low-dose group were above INR 3.5, whereas 13.76% of the values in the conventional-dose group were above this level (Fig 1). In Figure 3, the percentage of INR values in the target range is given in relation to schooling. In the German school system, comprehensive school is the lowest educational level and grammar school is the highest preuniversity educational level. Data show that educational level did not have a major influence. In Figure 4, the percentage of INR values in the target range is given according to age. Results showed no major difference between the age groups. During the entire observation period, 41 grade III complications occurred (32 bleeding events and 9 thromboembolisms). All but 3 complications occurred in the patients with an aortic valve replacement. Fifteen complications (3 thromboembolisms, 12 bleeding events) occurred in the low-dose INR group, whereas 26 complications (6 thromboembolisms, 20 bleeding events) occurred in the conventional-dose INR group. Fewer bleeding events and also slightly fewer cases of thromboembolism occurred in the low-dose group compared to the conventional-dose group (0.74% vs 1.20% and 0.18% vs 0.40%, respectively). In both cases the differences between the two study groups were not statistically significant (p and p 0.210, respectively). However, the total complication rate of bleeding and thromboembolic events tended to be lower in the low-dose group than in the conventional-dose group (Fig 5). In the patients with grade III thromboembolism, the mean INR values were 2.3 (range, 1.0 to 3.4) at week 4 preceding the insult, 2.5 (range, 1.0 to 3.7) at week 3, 2.4 (range, 1.4 to 4.4) at week 2, 2.3 (range, 1.4 to 3.1) at week 1, and 2.1 (range, 1.1 to 3.0) at week 0. Five of the 9 patients had at least one INR value below 1.8 during the 4 weeks before the complication occurred; however, in 2 patients INR values did not fall below 2.5. In those 15 patients with grade III bleeding events, where Fig 3. International normalized ratio (INR) values in patients with INR self-management according to schooling.
5 Ann Thorac Surg KOERTKE ET AL 2005;79: LOW-DOSE INR SELF-MANAGEMENT 1913 Fig 4. International normalized ratio (INR) values in patients with INR self-management in relation to age. the complication occurred was not induced by an external event, INR values were clearly below 3.5 INR, a value that is generally regarded as safe. In detail, mean INR values were 2.8 (range, 1.8 to 3.4) at week 4 preceding the insult, 2.8 (range, 1.8 to 3.4) at week 3, 2.9 (range, 1.8 to 4.0) at week 2, 3.0 (range, 1.7 to 4.8) at week 1, and 2.9 (range, 1.5 to 3.9) at week 0. Only 7 out of the 15 patients with a grade III bleeding event had at least one INR value above 3.5 during the 4 weeks before the complication occurred. In 3 patients a bleeding episode occurred although the measured INR values did not exceed 2.8. Twenty-eight patients died within 30 days of surgery (12 in the low-dose and 16 in the conventional-dose group). Twenty-one late deaths occurred in the low-dose group and 14 in the conventional-dose group. Only 1 patient (from the conventional-dose group) died because of an embolic event. The other causes of death were myocardial infarction (n 26), intraoperative death (n 6), unknown (n 4), multiorgan failure (n 11), atrial fibrillation (n 7), lung failure (n 1), renal failure (n 3), neoplasm (n 2), and other causes (n 2). Survival rate did not differ between study groups (Fig 6). Fig 5. Freedom from grade III complications (heart valve prosthesis thrombosis or severe thromboembolism that required inpatient treatment or caused long-term impairment, including transient ischemic attacks) in patients with low-dose or conventional-dose international normalized ratio self-management. Fig 6. Survival of patients with international normalized ratio self-management and low-dose or conventional dose of anticoagulation therapy. Comment This interim analysis of the ESCAT II study demonstrates that it is possible to maintain approximately 75% of the INR values in the target zone, even when the target range is narrow. Moreover, our data show that the incidence of thromboembolism and bleeding complications can be reduced to less than 2% per observation year in the conventional-dose INR group and to less than 1% per observation year in the low-dose INR group. It is encouraging that both types of complications tended to be lower in the low-dose group than in the conventional-dose group. Thus, our data do not support the results of a recent meta-analysis that indicated patients benefit from a target INR higher than 3.0 [8]. It should be mentioned, however, that our study design is based on a concept that enables the patients to perform INR measurements self-responsibly and also allows them to selfadjust the anticoagulation medication. The 24-hour care and consultation confirms the patients self-confidence, especially in those situations when questions and difficulties arise. Therefore, the results of our study and the data of that earlier meta-analysis must be compared with caution. We have already demonstrated in the ESCAT I study that patients whose INR values were measured by their family doctors had approximately 18% fewer INR values lying within the therapeutic range than did the self-management INR group (60% vs 78%) [4]. The incidence of hemorrhagic complications in the ESCAT I study was 2.6% in the patients whose INR measurements were managed by the family doctor and 1.7% in the group with conventional INR self-management. In the ESCAT II study, the incidence of hemorrhagic complications tended to be lower in both study groups (1.2% and 0.7%) compared with the ESCAT I study INR self-management group. These differences in hemorrhagic complications between ESCAT I and ESCAT II are most probably related to the differences in INR values. In those ESCAT II patients where almost all hemorrhagic complications occurred (patients with aortic valve prostheses), the mean INR values were only 2.8 in the conventional-dose INR group and 2.4 INR in the low-dose INR group; whereas in the ESCAT I study, the patients with INR self-management had a mean INR value of 3.0 [4].
6 1914 KOERTKE ET AL Ann Thorac Surg LOW-DOSE INR SELF-MANAGEMENT 2005;79: It should be mentioned that the INR zone that is necessary to minimize bleeding complications in patients who are on anticoagulation therapy is not well established. Hemorrhagic complications are reported to increase sharply when INR values are above 6.0 [11]. The number of INR values above this level was negligible (Fig 1) in our study. However, in a recent study a minimum risk of death occurred in patients with mechanical heart valve prostheses at an INR value of 2.3, while the risk of death from cerebral bleeding doubled with an increase of 1 U of INR above 2.5 [6]. Our data confirm the assumption that bleeding complications may occur in some patients with aortic valve prostheses who have relatively low INR values. Mean values in those patients with grade III bleeding complications were indeed only 2.9 INR within the last weeks before the complication occurred. Surprisingly, the values of some patients did not exceed 2.8 INR. Data indicate that the relatively low mean INR values in both ESCAT II groups may have contributed to the overall relatively low incidence of grade III bleeding complications. Consequently, a clear rationale exists to propagate a low range and narrow target zone of INR self-management. Moreover, the etiology of life-threatening hemorrhage under obviously adequate oral anticoagulation has to be further characterized in future studies. Without anticoagulation therapy, patients with mechanical prosthetic heart valves have an incidence of thromboembolism of 8.6% per observation year [12]. Some of our patients with thromboembolic events had INR values below 1.2, indicating effectively no anticoagulation. Nevertheless, it should be mentioned that in the ESCAT II study, even low-dose INR self-management was able to reduce the incidence of thromboembolism to below 0.5% per observation year. Data indicate that the target value of 1.8 INR is generally safe for the group with aortic valve prostheses and low-dose INR self-management. Moreover, this target range is close to the target range of 2.0 to 3.0 INR for aortic valve prostheses, which has recently been recommended [7]. An anticoagulation level of INR 3.0 to 4.0, as recommended in earlier years [13] for patients with heart valve prostheses, no longer seems to be the optimal anticoagulation therapy. Our data clearly demonstrate that low-dose INR self-management does not increase the risk of thromboembolism compared with conventional-dose INR self- management. Because the dropout rate of the study participants was less than 15%, it can be concluded that INR selfmanagement is generally well accepted by the patients. Our evaluation showed that the percentage of INR values within the target range was not influenced by age nor did educational level have a major impact. In conclusion, low-dose INR self-management is a promising tool to achieve low hemorrhagic complications without increasing the risk of thromboembolic complications. The combination of the low-dose of anticoagulants and the INR self-management may be responsible for these favorable results. The technique allows patients to avoid serious sequelae because of a phenprocoumon overdose. The concept of INR self-management is applicable, independent of age and educational level, for all patients in whom permanent anticoagulation therapy is indicated. References 1. Koerfer R, Koertke H. ESCAT early self-controlled anticoagulation trial. In: Krian A, ed. Advancing technology of bileaflet mechanical heart valves. Darmstadt, Germany: Steinkopf Verlag, 1998: Stein PD, Albert JS, Copeland JMG, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108 (suppl):371s 9S. 3. Jafri SM, Gheorghiade M, Goldstein S. Oral anticoagulation for secondary prevention after myocardial infarction with special reference to the warfarin re-infarction study. Prog Cardiovasc Dis 1992;34: Koertke H, Minami K, Bairaktaris A, Wagner O, Koerfer R. INR self-management following mechanical heart valve replacement. J Thromb Thrombolysis 2000;9:S Körtke H, Minami K, Breymann T, et al. INR selfmanagement after mechanical heart valve replacement: ESCAT (early self-controlled anticoagulation trial). Z Kardiol 2001;90(suppl 6):VI/ Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002;325: Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119(1 suppl):220s 7S. 8. Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003;108(suppl 1):II Vink R, Kraaijenhagen RA, Hutten BA, et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves. J Am Coll Cardiol 2003;42: Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53: Penning-van Beest FJ, Geleijnse JM, van Meegen E, Vermeer C, Rosendaal FR, Stricker BH. Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002;55: Schulman S. Care of patients receiving long-term anticoagulant therapy. New Engl J Med 2003;349: Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333;1995:11 7. DISCUSSION DR RALPH J. DAMIANO (St. Louis, MO): I have one question for you. It is a little hard for me to understand how maintaining a lower INR decreases the rate of thromboembolism, especially since both groups utilized self-management and maintained INR in a relatively tight range. It is pretty obvious that bleeding complications would be less, but how do you explain having a significantly lower risk of thromboembolism at a lower INR? DR SEIFERT: Since the variance is not so great, we feel that the variance from the top to the bottom actually causes the thromboembolism and not the sole value itself.
Self-Management of Oral Anticoagulation Therapy Improves Long-Term Survival in Patients With Mechanical Heart Valve Replacement
CARDIOVASCULAR ORIGINAL ARTICLES: CARDIOVASCULAR Self-Management of Oral Anticoagulation Therapy Improves Long-Term Survival in Patients With Mechanical Heart Valve Replacement Heinrich Koertke, MD, Armin
More informationAlthough numerous mechanical and biologic heart
International Normalized Ratio Self-Management After Mechanical Heart Valve Replacement: Is an Early Start Advantageous? Heinrich Körtke, MD, and Reiner Körfer, MD Department of Thoracic and Cardiovascular
More informationLow-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II
European Heart Journal (2007) 28, 2479 2484 doi:10.1093/eurheartj/ehm391 Clincial research Valvular heart disease Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationInternational Normalized Ratio Self-Management Lowers the Risk of Thromboembolic Events After Prosthetic Heart Valve Replacement
International Normalized Ratio Self-Management Lowers the Risk of Thromboembolic Events After Prosthetic Heart Valve Replacement Thomas Eitz, MD, Soren Schenk, MD, Dirk Fritzsche, MD, Andreas Bairaktaris,
More informationLong-term bleeding events after mechanical aortic valve replacement in patients under the age of 60
Neth Heart J (2015) 23:111 115 DOI 10.1007/s12471-014-0626-9 ORIGINAL ARTICLE Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60 B. M. Swinkels & B. A.
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationThe effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical mitral valve replacement
Bal et al. Journal of Cardiothoracic Surgery 2014, 9:79 RESEARCH ARTICLE Open Access The effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical
More informationMitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients
Mitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients Kazutomo Minami, MD, Armin Zittermann, PhD, Sebastian Schulte-Eistrup, MD, Heinrich Koertke, MD, and Reiner
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationCorrelation between demographic factors and warfarin stable dosage in population of Western China.
Biomedical Research 2017; 28 (19): 8249-8253 ISSN 0970-938X www.biomedres.info Correlation between demographic factors and warfarin stable dosage in population of Western China. Yongfeng Fan 1,2, Li Dong
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction
More informationLong-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationTelemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants
European Heart Journal (2015) 36, 1297 1305 doi:10.1093/eurheartj/ehu330 CLINICAL RESEARCH Thrombosis and antithrombotic therapy Telemedicine-guided, very low-dose international normalized ratio self-control
More informationIs there a place for new anticoagulants in prosthetic valves?
Is there a place for new anticoagulants in prosthetic valves? Patrizio Lancellotti, MD, PhD, FESC, FACC University of Liège Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, Department of Cardiology,
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationA Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center.
A Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center Lauren Martens Abstract This study sought to determine the total number of
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationWe present the case of an asymptomatic, 75-year-old
Images in Cardiovascular Medicine Asymptomatic Rupture of the Left Ventricle Lech Paluszkiewicz, MD; Stefan Ożegowski, MD; Mohammad Amin Parsa, MD; Jan Gummert, PhD, MD We present the case of an asymptomatic,
More informationThe Pendulum of Bridging Periprocedural Anticoagulant Therapy. Alan K. Jacobson, MD Cardiology Section Loma Linda VA Medical Center Loma Linda, CA
The Pendulum of Bridging Periprocedural Anticoagulant Therapy Alan K. Jacobson, MD Cardiology Section Loma Linda VA Medical Center Loma Linda, CA Disclosures Department of Veterans Affairs Industry Relationships:
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationPostanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare
Clinical Chemistry 52:10 1871 1878 (2006) Evidence-Based Laboratory Medicine and Test Utilization Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare Ann-Helen Kristoffersen,
More informationMechanical heart valves and Anticoagulation. Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital.
Mechanical heart valves and Anticoagulation Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital. Today s discussion: Case review The currently Available and most commonly
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationSimultaneous Aortic and Mitral Valve Replacement in Octogenarians: A Viable Option?
Simultaneous Aortic and Mitral Valve Replacement in Octogenarians: A Viable Option? Ariane Maleszka, MD,* Georg Kleikamp, MD, PhD,* Armin Zittermann, PhD, Maria R. G. Serrano, MD, and Reiner Koerfer, MD,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationMEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME MONITORING DEVICE. POLICY NUMBER: CATEGORY: Equipment/Supplies
MEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME 06/23/16, 6/22/17 PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationOn October 3, 1977, the first St. Jude Medical (SJM)
The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Robert W. Emery, MD, Christopher C. Krogh, Kit V. Arom, MD, PhD, Ann M. Emery, RN, Kathy Benyo-Albrecht,
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationThe ATS Medical Open Pivot heart valve (ATS Medical, 10-Year Experience With the ATS Mechanical Valve in the Mitral Position
10-Year Experience With the ATS Mechanical Valve in the Mitral Position Constantin Stefanidis, MD, Albert M. Nana, MD, Didier De Cannière, MD, PhD, Martine Antoine, MD, Jean-Luc Jansens, MD, Chi-Hoang
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationDespite improvements in valve design, stroke remains a serious
Surgery for Acquired Cardiovascular Disease Bando et al Early and late stroke after mitral valve replacement with a mechanical prosthesis: Risk factor analysis of a 24-year experience Ko Bando, MD a Junjiro
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationEVERYTHING ABOUT MECHANICAL VALVES HAS CHANGED
EVERYTHING ABOUT MECHANICAL VALVES HAS CHANGED 106180.001 CryoLife - New Brochure FIN.indd 1 06/10/2016 14:08 Why use another mechanical valve when 1 2 3 No other mechanical valve has: 1 90 leaflets: 1
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationThe Optimal Intensity of Vitamin K Antagonists in Patients With Mechanical Heart Valves Meta-Analysis
Journal of the American College of Cardiology Vol. 42, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.07.029
More informationIntroduction. Keywords: Infrainguinal bypass; Prognosis; Haemorrhage; Anticoagulants; Antiplatelets.
Eur J Vasc Endovasc Surg 30, 154 159 (2005) doi:10.1016/j.ejvs.2005.03.005, available online at http://www.sciencedirect.com on Risk of Major Haemorrhage in Patients after Infrainguinal Venous Bypass Surgery:
More informationCME/SAM. Bleeding Risks and Response to Therapy in Patients With INR Higher Than 9. Monica B. Pagano, MD, 1 and Wayne L. Chandler, MD 2.
Coagulation and Transfusion Medicine / Bleeding and Therapy With INR >9 Bleeding Risks and Response to Therapy in Patients With INR Higher Than 9 Monica B. Pagano, MD, 1 and Wayne L. Chandler, MD 2 Key
More informationSangho Rhie, M.D.*, Jun Young Choi, M.D.*, In Seok Jang, M.D.*, Jong Woo Kim, M.D.*, Chung Eun Lee, M.D.*, Hyun Oh Park, M.D.*
Korean J Thorac Cardiovasc Surg 2011;44:220-224 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) Clinical Research DOI:10.5090/kjtcs.2011.44.3.220 Relationship between the Occurrence of Thromboembolism
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationBehavior of Prothrombin Time (INR) in Response to Warfarin Therapy in a Thai Population
Behavior of Prothrombin Time (INR) in Response to Warfarin Therapy in a Thai Population Sarana Boonbaichaiyapruck,MD, FACC* Pradit Panchavinnin,MD.** Taworn Suthichaiyakul,MD.*** Thanawat Benjanuwatra,MD.****
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationMedical Apps for Cardiology Uses. There s an App for That!
Medical Apps for Cardiology Uses There s an App for That! Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationORIGINAL INVESTIGATION. Aharon Lubetsky, MD; Hagith Yonath, MD; David Olchovsky, MD; Ronen Loebstein, MD; Hillel Halkin, MD; David Ezra, MD
ORIGINAL INVESTIGATION Comparison of Oral vs Intravenous Phytonadione (Vitamin K 1 ) in Patients With Excessive Anticoagulation A Prospective Randomized Controlled Study Aharon Lubetsky, MD; Hagith Yonath,
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More information1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,
Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationPrognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards
European Heart Journal Supplements (1) 3 (Supplement Q), Q27 Q32 Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationComplicanze aritmiche in riabilitazione dopo CCH.
Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationGains and losses of warfarin therapy as performed in an anticoagulation clinic
Journal of Internal Medicine 2006; 259: 296 304 doi:10.1111/j.1365-2796.2005.01605.x Gains and losses of warfarin therapy as performed in an anticoagulation clinic A. M. NJAASTAD 1,U.ABILDGAARD 1 &J.F.LASSEN
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationUsing the Variability of INRs to indicate the Risk of an Event in DAWN AC
Predicting Clinical Events Using the Variability of INRs to indicate the Risk of an Event in DAWN AC Syd Stewart, Managing Director, 4S DAWN Clinical Software Introduction It is widely agreed that neither
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More information